A recent study published in Nature Communications highlights the transformative work of Stephen Oh and his team at Washington University School of Medicine in St. Louis. Their findings highlight the innovative targeting of RSK1, which offers new avenues for addressing myeloid malignancies, and reiterate the groundbreaking potential of PMD-026, developed by the team at Phoenix Molecular Designs, to transform cancer treatment and bring new hope to patients worldwide.

In the study, inhibiting RSK1 helped reverse the progression of myeloproliferative neoplasms (MPNs) in mice, significantly reducing fibrosis, or scar formation, in the bone marrow. Remarkably, inhibiting RSK1 eliminated up to 96% of cancer in mice after just four weeks, underscoring the transformative potential of this approach.

This collaboration showcases the power of innovative science and partnerships to advance precision medicine. We are proud that PMD-026 is contributing to this vital progress, bringing us closer to better outcomes for cancer patients everywhere.

Read more about this impactful research in Washington University’s news release: https://medicine.washu.edu/news/drug-in-clinical-trials-for-breast-cancer-could-also-treat-some-blood-cancers/